Safety and Immunogenicity of HEPLISAV™ a Hepatitis B Virus Vaccine in Adults on Hemodialysis
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 155 participants.
Also called NCT01195246
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose prevention
- Phase
- Phase 3
- Enrolled
- 155 participants
- Sponsor
- Dynavax Technologies Corporation
- Registry
-
NCT01195246 -
2010-019633-10
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Germany
- Registry status
- Completed
Technical summary
Registry record NCT01195246. Randomized; triple masking; primary purpose prevention. Start 2010-12 (registry gives no type); primary completion 2012-02 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Safety and Immunogenicity of HEPLISAV™ a Hepatitis B Virus Vaccine in Adults on Hemodialysis
- Condition
- End Stage Renal Disease
- Intervention (Biological)
- HEPLISAV
- Intervention (Biological)
- Engerix-B
- Intervention (Biological)
- Fendrix
- Lead sponsor
- Dynavax Technologies Corporation
Record details
- Record id
cardio:ct-nct01195246- Content hash
14970a2b865bf0dafe0f6ded1a308ecbd191e04989299366d24a9d855e07f13a